SLDB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Solid Biosciences Inc (SLDB) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are positive analyst ratings and potential upside, the lack of significant positive financial performance, insider selling, and no strong trading signals suggest holding off on investment for now.
The technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is below zero and negatively expanding, indicating bearish momentum. RSI is neutral at 50.409, and the stock is trading near its pivot level of 8.267 with key resistance at 8.747 and support at 7.787.
Leadership changes at the CBER are also seen as beneficial.
Insider selling has increased significantly (6640.99% over the last month), which may signal lack of confidence from those closest to the company. Additionally, the financial performance remains weak with negative net income (-$49.79M) and declining EPS (-47% YoY).
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$49.79M (though improved 16.88% YoY), and a significant drop in EPS (-47% YoY). The gross margin remains at 0%.
Analysts are bullish with multiple buy ratings and raised price targets. JPMorgan increased its target to $12, Guggenheim initiated coverage with a $26 target, and Wedbush raised its target to $17, citing potential upside to the high-$20s if accelerated approval is achieved.
